The correct version of this story can be read at https://www.equitiesfocus.com/2018/02/21/horseman-capital-management-ltd-buys-new-position-in-beigene-ltd-bgne.html. Maxim Group set a $120.00 price target on shares of Beigene and gave the company a "buy" rating in a research note on Tuesday, November 14th. BeiGene, Ltd. (NASDAQ:BGNE) has risen 36.36% since February 22, 2017 and is uptrending.
Analysts await BeiGene, Ltd. (NASDAQ:BGNE) to report earnings on March, 28. More interesting news about BeiGene, Ltd. (NASDAQ:BGNE) were released by: Quotes.Wsj.com and their article: "News BeiGene Ltd. ADRBGNE" published on January 31, 2016 as well as Schaeffersresearch.com's news article titled: "Biotech Stocks ImmunoGen, BeiGene Surge to New Highs" with publication date: July 06, 2017. Zacks Investment Research downgraded Beigene from a "hold" rating to a "sell" rating in a research note on Monday, November 13th. Orbimed Advisors LLC now owns 1,313,788 shares of the company's stock valued at $135,925,000 after purchasing an additional 26,200 shares during the last quarter. Finally, BidaskClub upgraded shares of Beigene from a "hold" rating to a "buy" rating in a research note on Friday, January 5th. The fund bought 46,200 shares of the company's stock, valued at approximately $4,515,000. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of "Buy" and a consensus price target of $96.67.Читайте также: Rubio defends NRA donations: 'People buy into my agenda'
The company has a debt-to-equity ratio of 0.20, a current ratio of 9.33 and a quick ratio of 9.27. Beigene has a 12-month low of $34.36 and a 12-month high of $148.43. The company has market cap of $8.59 billion. Following the transaction, the chief marketing officer now owns 1,000 shares in the company, valued at $98,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The shares were sold at an average price of $86.00, for a total transaction of $94,600.00. Quantbot Technologies LP acquired a new stake in shares of Beigene in the third quarter worth approximately $160,000. The stock was bought at an average price of $101.00 per share, with a total value of $199,999,998.00. Also, CEO John Oyler sold 85,906 shares of the business's stock in a transaction that occurred on Wednesday, November 29th. Orbimed Advisors LLC increased its stake in Beigene by 2.0% during the third quarter. The disclosure for this sale can be found here. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Beigene in the 3rd quarter valued at $248,000. Finally, Mackenzie Financial Corp bought a new stake in shares of Beigene in the 4th quarter valued at $250,000.
BeiGene, Ltd.is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317.При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2021 Copyright.
Автоматизированное извлечение информации сайта запрещено.
Код для вставки в блог